Robert F. Kennedy Jr. and I rarely see eye to eye, but I’ll grudgingly admit he’s not entirely wrong about food dyes, though ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...

Merck said today its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...